TrialThe oncologist2025

Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial.

Yanwei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.